BeStock  
Markets › Compare › SUPN vs TEVA

SUPN vs TEVA

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
SUPN · Supernus Pharmaceuticals$42.76 ▲ 0.90%
TEVA · Teva Pharmaceutical Industries$39.66 ▲ 0.33%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

79111143175207Oct 7, '25Apr 7, '26Oct 5, '26
  • SUPN -11.0%
  • TEVA +97.6%

Head to head

MetricSUPNTEVA
Price$42.76$39.66
Change today▲ 0.90%▲ 0.33%
Market cap$2.49B$46.26B
Return, 3 months-10.8%+14.5%
Return, year to date-14.0%+27.1%
Return, 1 year-11.5%+98.7%
P/E (TTM)-22.366.1
P/B2.46.0
P/E percentile vs own 5y–100th
Dividend yield––
Revenue growth (YoY, latest qtr)–-0.8%
Net profit growth (YoY)–-303.2%
Gross margin–52.5%
Operating margin–18.7%
Net margin–4.1%
Return on equity–9.7%
Analyst target vs. price+52.6%+13.5%
Analyst buy share100%100%
RSI (14)4658
30-day volatility26.2%30.8%
Max drawdown, 1 year-27.6%-21.8%
Trend readLeaning bearishStrong uptrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • TEVA is the largest of the group by market value.
  • TEVA has returned the most over the past year.
  • SUPN carries the lowest trailing P/E.
  • SUPN has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top